878 related articles for article (PubMed ID: 33537099)
1. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
[TBL] [Abstract][Full Text] [Related]
2. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in hepatocellular carcinoma.
Buonaguro L; Mauriello A; Cavalluzzo B; Petrizzo A; Tagliamonte M
Ann Hepatol; 2019; 18(2):291-297. PubMed ID: 31047849
[TBL] [Abstract][Full Text] [Related]
6. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
7. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
Jiang Y; Han QJ; Zhang J
World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma.
Ruan Q; Wang H; Burke LJ; Bridle KR; Li X; Zhao CX; Crawford DHG; Roberts MS; Liang X
Int J Cancer; 2020 Sep; 147(6):1519-1527. PubMed ID: 32010970
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors for hepatocellular carcinoma.
El Dika I; Khalil DN; Abou-Alfa GK
Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
12. Metadherin-driven promotion of cancer stem cell phenotypes and its effect on immunity in hepatocellular carcinoma.
Todorović N; Amedei A
World J Gastroenterol; 2024 May; 30(20):2624-2628. PubMed ID: 38855151
[TBL] [Abstract][Full Text] [Related]
13. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.
Rodríguez MM; Fiore E; Bayo J; Atorrasagasti C; García M; Onorato A; Domínguez L; Malvicini M; Mazzolini G
Mol Ther; 2018 Dec; 26(12):2738-2750. PubMed ID: 30301668
[TBL] [Abstract][Full Text] [Related]
14. Immunological landscape and immunotherapy of hepatocellular carcinoma.
Prieto J; Melero I; Sangro B
Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
[TBL] [Abstract][Full Text] [Related]
15. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
16. Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis.
Singh D; Khan MA; Siddique HR
Biochem Pharmacol; 2022 Apr; 198():114955. PubMed ID: 35181312
[TBL] [Abstract][Full Text] [Related]
17. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
[TBL] [Abstract][Full Text] [Related]
18. Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4
Lo Re O; Mazza T; Giallongo S; Sanna P; Rappa F; Vinh Luong T; Li Volti G; Drovakova A; Roskams T; Van Haele M; Tsochatzis E; Vinciguerra M
Theranostics; 2020; 10(2):910-924. PubMed ID: 31903159
[No Abstract] [Full Text] [Related]
19. Tumor dormancy and cancer stem cells: two sides of the same coin?
Kleffel S; Schatton T
Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
